Advances in miRNA Research in Hepatocellular Carcinoma

Erqi Li(Affiliated Hospital of Chengde Medical College)
Bin Zheng(Affiliated Hospital of Chengde Medical College)
Jian Li(Affiliated Hospital of Chengde Medical College)

Abstract

Globally, Hepatocellular carcinoma (HCC) is recognized as a major malignant tumor, being the 6th most common in terms of occurrence and ranking third in mortality rates among all cancer types. Within China, HCC is noted as the fourth most prevalent cancer and the second most common cause of cancer-related fatalities. The difficulty in managing HCC stems from its tendency to remain undetected due to a lack of symptoms in the early stages, along with the current lack of both effective diagnostic techniques and treatments for chemotherapy.

MiRNA, also referred to as microRNA, is a type of non-coding RNA typically consisting of 19-22 nucleotides in length. Upon binding to the mRNA of target genes, it functions to suppress mRNA translation or induce mRNA degradation, thereby exerting regulatory control over gene expression. Recent research increasingly suggests the pivotal involvement of miRNA in the onset and progression of primary hepatic cells. Studies exploring the association between miRNA and primary hepatic cell carcinoma hold substantial clinical significance in elucidating the pathogenesis, facilitating diagnosis, and advancing treatment modalities for liver cancer.

Keywords

Hepatocellular carcinoma; miRNA

References

Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells. 2020;9(6):1370. Published 2020 Jun 1.

Oura K, Morishita A, Masaki T. Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review. Int J Mol Sci. 2020;21(21):8362. Published 2020 Nov 7.

Wei L, Wang X, Lv L, et al. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer. 2019;18(1):147. Published 2019 Oct 25. doi:10.1186/s12943-019-1086-z

Sung H，Ferlay J，Siegel RL，et al．Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin，CA Cancer J Clin. 2021;71(3):209-249

Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314.

Oura K, Morishita A, Masaki T. Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review. Int J Mol Sci. 2020;21(21):8362.

Han TS, Hur K, Cho HS, Ban HS. Epigenetic Associations between lncRNA/circRNA and miRNA in Hepatocellular Carcinoma. Cancers (Basel). 2020;12(9):2622. Published 2020 Sep 14.

Sengupta D, Deb M, Kar S, et al. Dissecting miRNA facilitated physiology and function in human breast cancer for therapeutic intervention. Semin Cancer Biol. 2021;72:46-64.

Sancer O, Koşar PA, Tefebaşı MY, Ergün O, Demir M, Koşar A. Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia. Turk J Med Sci. 2022;52(3):788-795.

Gebrekiristos M, Melson J, Jiang A, Buckingham L. DNA methylation and miRNA expression in colon adenomas compared with matched normal colon mucosa and carcinomas. Int J Exp Pathol. 2022;103(3):74-82.

Lee RC, Feinbaum RL, Ambros V The C elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854.

Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature,2000. February 24;403(6772):901–906.

Slack FJ, Basson M, Liu Z, et al. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. Mol Cell. 2000. 5(4):659–669

Gilles ME, Slack FJ. Let-7 microRNA as a potential therapeutic target with implications for immunotherapy. Expert Opin Ther Targets. 2018 Nov;22(11):929-939.

Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993. December 3;75(5):843–854.

Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000. February 24;403(6772):901–906.

Kozomara A., Birgaoanu M., Griffiths-Jones S. miRBase: From microRNA sequences to function. Nucleic Acids Res. 2019;47:D155–D162. [18]Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech. 2021 Apr 1;14(4):dmm047662. Yoon, A. J., Wang, S., Kutler, D. I., Carvajal, R. D., Philipone, E., Wang, T., Peters, S. M., Laroche, D., Hernandez, B. Y. and Mcdowell, B. D. (2020)

Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24.

Oura K, Morishita A, Masaki T. Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review. Int J Mol Sci. 2020 Nov 7;21(21):8362. [24]Esquela-Kerscher A., Slack F.J.J. Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer. 2006;6:2596–2599.

Esquela-Kerscher A., Slack F.J.J. Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer. 2006;6:2596–2599. doi: 10.1038/nrc1840.

Bartel D.P.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.

Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech. 2021 Apr 1;14(4):dmm047662. doi: 10.1242/dmm.047662. Epub 2021 Apr 15. PMID: 33973623; PMCID: PMC8077553.

Liu R，Chen Y，Liu G，et al．PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers．Cell Death Dis. 2020;11(9):797

Ali Syeda Z, Langden SSS, Munkhzul C, Lee M, Song SJ. Regulatory Mechanism of MicroRNA Expression in Cancer. Int J Mol Sci. 2020 Mar 3;21(5):1723.

Trabucchi, M. and Mategot, R. (2019). Subcellular heterogeneity of the microRNA machinery. Trends Genet. 35, 15-28. 10.1016/j.tig.2018.10.006

Di Leva G., Garofalo M., Croce C.M. MicroRNAs in cancer. Annu. Rev. Pathol. 2014;9:287–314. doi: 10.1146/annurev-pathol-012513-104715

varez-Garcia V，Tawil Y，Wise HM，et al． Mechanisms of PTEN loss in cancer: It's all about diversity．Semin Cancer Biol. 2019;59:66-79

Monya, B., 2010. MicroRNA profifiling: separating signal from noise. Nat. Methods 7, 687–692.

Tili E, Croce CM, Michaille JJ. (2009). miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol, 28(5):264–84

Vigorito E, Kohlhaas S, Lu D, et al. (2013). miR-155: an ancient regulator of the immune system. Immunol Rev, 253(1):146–57

Lao TD, Nguyen MT, Nguyen DH, Le TAH. Upregulation of miRNA-155 in Nasopharyngeal Carcinoma Patients. Iran J Public Health. 2021 Aug;50(8):1642-1647. PMID: 34917535; PMCID: PMC8643532.

Qu, Y., Zhang, H., Sun, W., Han, Y., Li, S., Qu, Y., … Ba, Y. (2018).MicroRNA‐155 promotes gastric cancer growth and invasion by

negatively regulating transforming growth factor‐β receptor 2. Cancer

Science, 109(3), 618–628

Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019 May;234(5):5451-5465.

Liu HY, Zhang YY, Zhu BL, Feng FZ, Yan H, Zhang HY, Zhou B. miR-21 regulates the proliferation and apoptosis of ovarian cancer cells through PTEN/PI3K/AKT. Eur Rev Med Pharmacol Sci. 2019 May;23(10):4149-4155. PMID: 31173285.

Tang J, Li X, Cheng T, Wu J. miR-21-5p/SMAD7 axis promotes the progress of lung cancer. Thorac Cancer. 2021 Sep;12(17):2307-2313. [36]Liao, Y.C., Lin, T.H., Chen, C.Y., Lin, S.B., Au, L.C., 2014. The antileukemia activity of natural product HQ17(3) is possibly associated with downregulation of miR-17-92 cluster. Biomed. Res. Int. 2014, 306718.

Farsad K，Nabavizadeh N，Kardosh A，et al．Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally，the future is obscure． Ann Transl Med. 2020;8(24):1700

Aqeilan, R.I., Calin, G.A., Croce, C.M., 2010. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 17, 215–220.

Wang C, Jia Q, Guo X, Li K, Chen W, Shen Q, Xu C, Fu Y. microRNA-34 family: From mechanism to potential applications. Int J Biochem Cell Biol. 2022 Mar;144:106168. doi: 10.1016/j.biocel.2022.106168. Epub 2022 Jan 24. PMID: 35085803.

Liu, L., Ren, W., & Chen, K. (2017). MiR‐34a promotes apoptosis and inhibits autophagy by targeting HMGB1 in acute myeloid leukemia

cells. Cellular Physiology and Biochemistry, 41(5), 1981–1992.

Fu W, Hong Z, You X, Din J, Chen B, Zhao B, Yuan G, Li Q. Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer. Biomed Pharmacother. 2019;118:109374.

Imani S, Wu RC, Fu J. MicroRNA-34 family in breast cancer: from research to therapeutic potential. J Cancer. 2018 Sep 28;9(20):3765-3775.

Sun D, Li H, Cao M, et al. Cancer burden in China: trends, risk factors and prevention. Cancer Biol Med. 2020;17(4):879-895.

Bai X， Zheng L, Xu Y, Liang Y, Li D. Role of microRNA-34b-5p in cancer and injury: how does it work? Cancer Cell Int. 2022 Dec 1;22(1):381.

Zhang G.L., Li Y.X., Zheng S.Q., Liu M., Li X., Tang H.H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antivir. Res. 2010;88:169–175.

Niepmann M., Shalamova L.A., Gerresheim G.K., Rossbach O.O. Signals involved in regulation of hepatitis C virus RNA genome translation and replication. Front. Microbiol. 2018;9:395.

Niepmann M., Gerresheim G.K.K. Hepatitis C virus translation regulation. Int. J. Mol. Sci. 2020;21:2328.

Pineau P., Volinia S., McJunkin K., Marchio A., Battiston C., Terris B., Mazzaferro V., Lowe S.W., Croce C.M., Dejean A.A. miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. USA. 2010;107:264–269.

Luo X., Zhang D., Xie J., Su Q., He X., Bai R., Gao G., Pan W.W. MicroRNA-96 Promotes Schistosomiasis hepatic fibrosis in mice by suppressing Smad7. Mol. Methods Clin. Dev. 2018;11:73–82.

Zhang T., Yang Z., Kusumanchi P., Han S., Liangpunsakul S.S. Critical role of microRNA-21 in the pathogenesis of liver diseases. Front. Med. (Lausanne) 2020;7:7.

Guo X., Lv X., Lv X., Ma Y., Chen L., Chen Y.Y. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis. Oncotarget. 2017;8:44050–44058.

Zhang T, Yang Z, Kusumanchi P, Han S, Liangpunsakul S. Critical Role of microRNA-21 in the Pathogenesis of Liver Diseases. Front Med (Lausanne). 2020 Jan 31;7:7. doi: 10.3389/fmed.2020.00007. PMID: 32083086; PMCID: PMC7005070.

Su H., Yang J.R., Xu T., Huang J., Xu L., Yuan Y., Zhuang S.M.M. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 2009;69:1135–1142.

Kwon J.J., Factora T.D., Dey S., Kota J.J. A systematic review of miR-29 in Cancer. Mol. Ther. Oncolytics. 2019;12:173–194.

Yang J, Gong X, Yang J, Ouyang L, Xiao R, You X, Ouyang Y. Suppressive role of microRNA-29 in hepatocellular carcinoma via targeting IGF2BP1. Int J Clin Exp Pathol. 2018 Mar 1;11(3):1175-1185.

Cheng D., Deng J., Zhang B., He X., Meng Z., Li G., Ye H., Zheng S., Wei L., Deng X., et al. LncRNA HOTAIR epigenetically suppresses miR-122 expression in hepatocellular carcinoma via DNA methylation. EBioMedicine. 2018;36:159–170.

Komoll RM, Hu Q, Olarewaju O, von Döhlen L, Yuan Q, Xie Y, Tsay HC, Daon J, Qin R, Manns MP, Sharma AD, Goga A, Ott M, Balakrishnan A. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. J Hepatol. 2021 Jan;74(1):122-134.

Dharanija, M., Katarina, C., Burwinkel, B., Rongxi, Y., 2013. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front. Genet. 4, 116–127.

Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci. 2022 Jan 1;18(2):536-551.

Ludwig, N., Leidinger, P., Becker, K., Backes, C., Fehlmann, T., Pallasch, C., Keller, A. (2016). Distribution of miRNA expression across human tissues. Nucleic Acids Research, 44(8), 3865-3877.

Ho PTB, Clark IM, Le LTT. MicroRNA-Based Diagnosis and Therapy. Int J Mol Sci. 2022 Jun 28;23(13):7167. doi: 10.3390/ijms23137167.

Hung C.H., Hu T.H., Lu S.N., Kuo F.Y., Chen C.H., Wang J.H., Huang C.M., Lee C.M., Lin C.Y., Yen Y.H., et al. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. Int. J. Cancer. 2016;138:714-720.

Febit Holding GmbH, 2012. miRNA in the diagnosis of ovarian cancer. EP 2531611.Flavie, S., Marion, G., Hubert, L., Louis, B., Pierre, C., 2013. Targeting miR-21 for the therapy of pancreatic cancer. Mol. Ther. 21, 986-994.

DOI: http://dx.doi.org/10.26549/jams.v7i1.15782